H Maecke
01.12.2012
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab
Forrer F, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging 2012; 56:544-50.
01.12.2012Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab
01.12.2012Q J Nucl Med Mol Imaging 2012; 56:544-50
Forrer Flavio, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A
Weiter
01.04.2005
Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours
Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2005; 32:511-2; author reply 513.
01.04.2005Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours
01.04.2005Eur J Nucl Med Mol Imaging 2005; 32:511-2; author reply 513
Forrer Flavio, Mueller-Brand J, Maecke H
Weiter